Form 4: UTHR CEO Sells Shares Under Pre-Arranged 10b5-1 Plan

United Therapeutics CEO Martine Rothblatt executed pre-arranged stock option exercises and sales totaling 8,000 shares of common stock.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, executed transactions under a pre-arranged 10b5-1 trading plan.
• On September 19, 2025, 4,000 stock options were exercised at $120.26 per share and subsequently sold at a weighted average price of $411.0775 per share.
• On September 22, 2025, another 4,000 stock options were exercised at $120.26 per share. These shares were then sold in two separate transactions at weighted average prices of $416.7188 (2,000 shares) and $417.8875 (2,000 shares).
• Following these transactions, the reporting person beneficially owns 130 shares directly and 644,393 shares indirectly through various family trusts.
• The 10b5-1 plan, established on May 2, 2025, is set to continue until the earlier of the exhaustion of a tranche of 294,000 stock options that expire March 15, 2026, or December 31, 2025.
• After these transactions, 250,000 derivative securities (stock options) remain beneficially owned.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's an insider sale, it's pre-arranged under a 10b5-1 plan, which mitigates negative signaling. The significant profit realized by the executive from the option exercise and sale reflects positively on the company's stock performance.

Positives

• The significant spread between the exercise price of $120.26 and the sale prices (ranging from $411.0775 to $417.8875) indicates substantial profitability for the reporting person from these transactions.
• The execution of transactions under a pre-arranged 10b5-1 plan demonstrates a structured approach to insider stock sales, often used for personal financial planning and diversification.

Negatives

• The sale of shares by a key executive, even under a 10b5-1 plan, could be perceived by some investors as a lack of confidence, although this is typically a routine event for diversification or liquidity.

Future Outlook

The 10b5-1 trading plan is scheduled to continue until the earlier of the exhaustion of a tranche of 294,000 stock options expiring March 15, 2026, or December 31, 2025, indicating further pre-scheduled transactions may occur.

Industry Context

This filing represents a routine insider transaction for a publicly traded company, common across all industries, and does not provide specific insights into broader industry trends or competitive landscape for United Therapeutics Corp.

Related Party Transactions

• Shares are held indirectly in various family trusts where the Reporting Person and/or immediate family members are beneficiaries, or where the spouse is trustee/beneficiary, or the Reporting Person is trustee/beneficiary.

Stakeholder Impact

• Shareholders: The transactions are routine insider sales under a pre-arranged plan and are unlikely to have a significant direct impact on the company's operational or strategic direction. The high sale price reflects positively on shareholder value creation.
• Management: The transactions represent a personal financial event for the CEO, allowing for diversification and liquidity, consistent with executive compensation practices.

Next Steps

• Continuation of the pre-arranged 10b5-1 trading plan until its specified termination conditions are met (exhaustion of options or December 31, 2025).

Key Dates

Recommendation

This Form 4 filing details routine insider transactions (exercise and sale of stock options) executed under a pre-arranged 10b5-1 trading plan. Such transactions are typically for personal financial planning and diversification and do not signal new fundamental information about the company's performance or future prospects. Therefore, this filing alone does not warrant a change in investment thesis, and a 'hold' recommendation is appropriate.

Keywords

UTHR, United Therapeutics, Martine Rothblatt, Form 4, Insider Trading, Stock Options, 10b5-1 Plan, Executive Compensation